A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...

There was no clearance of other HPV types induced by Vvax001 ... “Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16 ...

The Cancer Vaccines Market is witnessing significant expansion, driven by rising cancer prevalence and advancements in ...

The following year licensed rights to a therapeutic HPV vaccine, in a deal that involved an upfront payment of $9 million-plus milestone payments that could take the total to $171 million.